{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sperry MM"],"funding":["Margarita Salas Postdoctoral grant","Army Research Office"],"pagination":["RP93796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11421850"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["Drugs that induce reversible slowing of metabolic and physiological processes would have great value for organ preservation, especially for organs with high susceptibility to hypoxia-reperfusion injury, such as the heart. Using whole-organism screening of metabolism, mobility, and development in <i>Xenopus</i>, we identified an existing drug, SNC80, that rapidly and reversibly slows biochemical and metabolic activities while preserving cell and tissue viability. Although SNC80 was developed as a delta opioid receptor activator, we discovered that its ability to slow metabolism is independent of its opioid modulating activity as a novel SNC80 analog (WB3) with almost 1000 times less delta opioid receptor binding activity is equally active. Metabolic suppression was also achieved using SNC80"],"journal":["eLife"],"pubmed_title":["Identification of pharmacological inducers of a reversible hypometabolic state for whole organ preservation."],"pmcid":["PMC11421850"],"funding_grant_id":["UNI/551/2021","W911NF-19-2-0027"],"pubmed_authors":["Kuelker A","Kaki S","Lin T","Veraza R","Lopez R","Martinez R","Sheehan K","Charrez B","Weitzel EK","Wood DM","Parry OG","Sesay AM","Ingber DE","Andrijauskaite K","Cox-Hinshaw J","Pena JJ","Sperry MM","Gardner E","Pilobello K","Hinshaw CJ","Lightbown S","Shcherbina K","Del Campo D","Cisneros E","Sleeter JJ","Maxwell Z","Percival TJ","Marquez S","Takeda T","Levin M","Novak R","Super M","Moore J","Plaza-Oliver M","Yracheta J","Homas ZT","Cano I","Jessop I","Lewandowski M","Izadifar Z","Fotowat H","Bunegin L"],"additional_accession":[]},"is_claimable":false,"name":"Identification of pharmacological inducers of a reversible hypometabolic state for whole organ preservation.","description":"Drugs that induce reversible slowing of metabolic and physiological processes would have great value for organ preservation, especially for organs with high susceptibility to hypoxia-reperfusion injury, such as the heart. Using whole-organism screening of metabolism, mobility, and development in <i>Xenopus</i>, we identified an existing drug, SNC80, that rapidly and reversibly slows biochemical and metabolic activities while preserving cell and tissue viability. Although SNC80 was developed as a delta opioid receptor activator, we discovered that its ability to slow metabolism is independent of its opioid modulating activity as a novel SNC80 analog (WB3) with almost 1000 times less delta opioid receptor binding activity is equally active. Metabolic suppression was also achieved using SNC80","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-04T14:49:06.749Z","creation":"2025-04-19T19:28:53.761Z"},"accession":"S-EPMC11421850","cross_references":{"pubmed":["39316042"],"doi":["10.7554/eLife.93796"]}}